Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Monsanto Company (MON) Is in Spotlight Today?

Page 1 of 2

Monsanto Company (NYSE:MON) shares are up almost 3% after the analysts at Jefferies upgraded the stock to ‘Buy’ from ‘Hold’ and bumped up their price target to $132 from $95 per share. The analysts think an increased takeover offer of $130 or more from Bayer is highly probable as the company tries to acquire Monsanto. Monsanto previously rejected Bayer’s $122 offer as too low, but hasn’t rejected the deal in principle. The company could be amenable to a sale if the offer were raised. There is also the possibility that Bayer might go hostile in its attempt to take over Monsanto.

Hedge funds seem to be betting on a successful deal, as the number of long hedge fund bets increased by 13 lately. MON was in 51 hedge funds’ portfolios at the end of the first quarter of 2016, compared to 38 hedge funds in our database with MON holdings at the end of the previous quarter. At the end of this article we will also compare MON to other stocks, including Syngenta AG (ADR) (NYSE:SYT), Cognizant Technology Solutions Corp (NASDAQ:CTSH), and Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) to get a better sense of its popularity.

Follow Monsanto Co W/ (NYSE:MON)
Trade (NYSE:MON) Now!

At the moment there are many signals market participants can use to evaluate stocks. A couple of the most under-the-radar signals are hedge fund and insider trading interest. Our experts have shown that, historically, those who follow the best picks of the top hedge fund managers can outperform the S&P 500 by a very impressive amount (see the details here).

According to publicly-available hedge fund and institutional investor holdings data compiled by Insider Monkey, Larry Robbins’ Glenview Capital has the largest position in Monsanto Company (NYSE:MON), worth close to $973.2 million, comprising 7.1% of its total 13F portfolio. Coming in second is John H. Scully’s SPO Advisory Corp, with a $318.6 million position; 5.8% of its 13F portfolio is allocated to the stock. Remaining peers with similar optimism consist of Ricky Sandler’s Eminence Capital, Ken Griffin’s Citadel Investment Group and John Overdeck and David Siegel’s Two Sigma Advisors.

As industry-wide interest jumped, key money managers have been driving this bullishness. On the next page, we are going to take a look at some funds that added Monsanto to their equity portfolio between January and March.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!